SCHEMBL6319425

SCHEMBL6319425

NC(=O)CC(O)CN1CCCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ATM Q13315 2/20 0.54
MAPT P10636 1/20 0.54
HSD17B10 Q99714 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.45
ANPEP P15144 1/20 0.41
ERAP2 Q6P179 1/20 0.41
CYP2D6 P10635 2/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
USP2 O75604 1/20 0.39
ABCB1 P08183 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAD52 P43351 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509344 0.82 USP2 (0.64) ATMHSD17B10L3MBTL1ANPEPCYP2D6
SCHEMBL4493204 0.82 USP2 (0.64) ATMHSD17B10L3MBTL1ANPEPCYP2D6
SCHEMBL4495691 0.82 USP2 (0.64) ATMHSD17B10L3MBTL1ANPEPCYP2D6
SCHEMBL402459 0.79 MEN1 (0.58) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL10895166 0.77 MEN1 (0.94) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL11118757 0.74 MEN1 (1.00) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL5254183 0.74 MEN1 (0.50) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL5243859 0.74 MEN1 (0.50) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL10476 0.73 MEN1 (0.68) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL22034681 0.73 MEN1 (0.68) MEN1KMT2AATMMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-6797725-B2 SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS SUGEN, INC. 2004-09-28 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives SUGEN. INC. 2003-05-29 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 MEN1 4419/4885KMT2A 1573/4885ATM 732/4885
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives PLK2, CDK2, PDPK1 MEN1 3621/4885KMT2A 1772/4885ATM 557/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 MEN1 4419/4885KMT2A 1573/4885ATM 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.